Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995).
The new long-acting somatostatin analogue octreotide (SMS 201-995) was investigated for its influence on secretagogue-stimulated human exocrine pancreatic secretion. Eighteen healthy volunteers participated in the study. During duodenal intubation with a background stimulation of either secretin 1 U.kg/h or secretin 1 U.kg/h + ceruletide, 120 ng.kg/h, octreotide was infused at doses of 5, 20 and 80 micrograms/h in a placebo-controlled randomized double-blind crossover trial. Duodenal juice samples were collected in 10-min intervals, and amylase, trypsin, chymotrypsin, and bicarbonate were measured in the individual fractions. During secretin stimulation, amylase was inhibited between 41 and 59%, trypsin between 28 and 72%, chymotrypsin between 55 and 70%, and bicarbonate between 0 and 31% with 5, 20 and 80 micrograms/h octreotide. During secretin and ceruletide stimulation, amylase was significantly inhibited by 84%, 78%, 81%, trypsin by 76%, 55%, 52%, chymotrypsin by 77%, 55%, 60%, and bicarbonate by 25%, 11%, 19% with 5, 20, and 80 micrograms/h octreotide, respectively (all decreases P less than 0.05). The long-acting somatostatin analogue octreotide was confirmed to be a potent inhibitor of stimulated human exocrine pancreatic secretion. The near maximal inhibitory potency of octreotide was achieved at a dose of only 5 micrograms/h. This finding may be of value in the planning of therapeutic studies with octreotide.
Department of Internal Medicine II, University of Ulm, FRG.
T P
TP
Kemmer
P
P
Malfertheiner
M
M
Büchler
H
H
Friess
L
L
Meschenmoser
H
H
Ditschuneit
D000328:Adult; D000681:Amylases / Q000378:metabolism; D001639:Bicarbonates / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology; D002918:Chymotrypsin / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D011863:Radioimmunoassay; D011897:Random Allocation; D012633:Secretin / Q000494:pharmacology; D014357:Trypsin / Q000378:metabolism
D001639:Bicarbonates; D012633:Secretin; D002108:Ceruletide; D000681:Amylases; D002918:Chymotrypsin; D014357:Trypsin; D015282:Octreotide